{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:28:25Z","timestamp":1769732905373,"version":"3.49.0"},"reference-count":44,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NA"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA.<\/ns4:p>","DOI":"10.12688\/f1000research.22577.1","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T10:45:08Z","timestamp":1594637108000},"page":"697","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Recent advances in managing axial spondyloarthritis"],"prefix":"10.12688","volume":"9","author":[{"given":"Priyanka","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"77-87","DOI":"10.1177\/2040622317743486","article-title":"New advances in the understanding and treatment of axial spondyloarthritis: From chance to choice.","volume":"9","author":"S Dubash","year":"2018","journal-title":"Ther Adv Chronic Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"641-52","DOI":"10.1080\/14712598.2018.1468884","article-title":"Biologics for treating axial spondyloarthritis.","volume":"18","author":"A Jones","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"556-62","DOI":"10.1016\/j.semarthrit.2014.10.009","article-title":"The burden of non-radiographic axial spondyloarthritis.","volume":"44","author":"A Boonen","year":"2015","journal-title":"Semin Arthritis Rheum."},{"key":"ref-4","doi-asserted-by":"crossref","first-page":"815-27","DOI":"10.1016\/S0889-857X(05)70043-0","article-title":"Quality of life in patients with ankylosing spondylitis.","volume":"24","author":"M Ward","year":"1998","journal-title":"Rheum Dis Clin North Am."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1285-99","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.","volume":"71","author":"M Ward","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"978-91","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"D van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1756-65","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial.","volume":"52","author":"A Wanders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1623-9","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.","volume":"71","author":"F Kroon","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1438-43","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: Results from a randomised multicentre trial (ENRADAS).","volume":"75","author":"J Sieper","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1616-22","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort.","volume":"71","author":"D Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2018-eular.1401","article-title":"SAT0278 Nsaids reduces radiographic progression in sacloiliac joints in early axial spondyloarthritis.","volume":"77","author":"D Rumiantceva","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"479-86","DOI":"10.1007\/s40744-019-00170-x","article-title":"New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review.","volume":"6","author":"F Perrotta","year":"2019","journal-title":"Rheumatol Ther."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"117-21","DOI":"10.1080\/03009742.2017.1347276","article-title":"High-intensity cardiorespiratory and strength exercises reduced emotional distress and fatigue in patients with axial spondyloarthritis: A randomized controlled pilot study.","volume":"47","author":"S Sveaas","year":"2018","journal-title":"Scand J Rheumatol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"313-6","DOI":"10.1093\/rheumatology\/kew223","article-title":"BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.","volume":"56","author":"L Hamilton","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"2441-51","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.","volume":"392","author":"D van der Heijde","year":"2018","journal-title":"Lancet."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"599-611","DOI":"10.1002\/art.40753","article-title":"Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.","volume":"71","author":"A Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"176-85","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).","volume":"79","author":"M Dougados","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"53-64","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): A randomised, placebo-controlled trial.","volume":"395","author":"A Deodhar","year":"2020","journal-title":"Lancet."},{"key":"ref-19","article-title":"Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study [abstract].","volume":"71","author":"A Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref-20","article-title":"Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active, Psa: Results from a 48-Week Phase 2b, Randomized, Double Blind, Placebo-Controlled, Dose- Ranging Study.","volume":"70","author":"C Ritchlin","year":"2018","journal-title":"Abstr Arthritis Rheumatol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"195.1-195","DOI":"10.1136\/annrheumdis-2019-eular.6888","article-title":"OP0234 Efficacy and safety of Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis: a 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study","volume":"78","author":"J Wei","year":"2019"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/annrheumdis-2018-eular.2380","article-title":"OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study.","volume":"77","author":"V Mazurov","year":"2018","journal-title":"Annals of the Rheumatic Diseases."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1340-7","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study.","volume":"76","author":"D van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"2378-87","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, placebo-controlled, phase 2 trial.","volume":"392","author":"D van der Heijde","year":"2018","journal-title":"Lancet."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"2108-17","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial.","volume":"394","author":"D van der Heijde","year":"2019","journal-title":"Lancet."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1041-5","DOI":"10.1136\/ard.2004.020800","article-title":"Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study.","volume":"63","author":"A Tan","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"296-8","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks.","volume":"64","author":"H Haibel","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"1108-10","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: An open-label, 24-week pilot study.","volume":"70","author":"I Song","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"1290-7","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial.","volume":"62","author":"I Song","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"305-6","DOI":"10.1136\/annrheumdis-2012-201926","article-title":"One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare.","volume":"72","author":"I Song","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"95-100","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomised, placebo-controlled trials.","volume":"73","author":"J Sieper","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"1051-7","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).","volume":"74","author":"J Sieper","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1475-80","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.","volume":"72","author":"E Pathan","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1295-302","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept, Dose-Finding Phase 2 Study.","volume":"77","author":"D Baeten","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"258-70","DOI":"10.1002\/art.40728","article-title":"Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.","volume":"71","author":"A Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1015-8","DOI":"10.1136\/annrheumdis-2018-213654","article-title":"Why Did IL-23p19 Inhibition Fail in AS: A Tale of Tissues, Trials or Translation?","volume":"78","author":"S Siebert","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"ref-37","article-title":"WHO Expert Committee on Biological Standardization, Sixtieth report (19-23 October 2009)"},{"key":"ref-38","article-title":"January 2017 Position statement: biosimilar medicines"},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"165-74","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based Recommendations for the Use of Biosimilars to Treat Rheumatological Diseases.","volume":"77","author":"J Kay","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"733-49","DOI":"10.1002\/art.41206","article-title":"Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.","volume":"72","author":"P Karmacharya","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"269-78","DOI":"10.1007\/s40261-020-00886-7","article-title":"Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients With Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).","volume":"40","author":"X Baraliakos","year":"2020","journal-title":"Clin Drug Investig."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"629-30","DOI":"10.1136\/ard.2010.128462","article-title":"'Treat to Target': Moving Targets From Hypertension, Hyperlipidaemia and Diabetes to Rheumatoid Arthritis.","volume":"69","author":"D Atar","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"344-8","DOI":"10.1097\/BOR.0000000000000625","article-title":"Treat-to-target in Axial Spondyloarthritis: Gold Standard or Fools' Gold?","volume":"31","author":"P Machado","year":"2019","journal-title":"Curr Opin Rheumatol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"3-17","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.","volume":"77","author":"J Smolen","year":"2018","journal-title":"Ann Rheum Dis."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-697\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-697\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-697\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T10:50:09Z","timestamp":1594637409000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-697\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":44,"URL":"https:\/\/doi.org\/10.12688\/f1000research.22577.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.24923.r66604","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.24923.r66605","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-697\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.24923.r66605, Daniel Wendling, Department of Rheumatology, CHRU Besan\u00e7on, Besan\u00e7on, France, 13 Jul 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-697\/v1#referee-response-66605","order":0,"name":"referee-response-66605","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.24923.r66604, Peter Cheung, Division of Rheumatology, National University Hospital, Singapore, Singapore, 13 Jul 2020, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/9-697\/v1#referee-response-66604","order":1,"name":"referee-response-66604","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}